CN102574914A - 改进的抗血清清蛋白结合性单可变区 - Google Patents

改进的抗血清清蛋白结合性单可变区 Download PDF

Info

Publication number
CN102574914A
CN102574914A CN2010800414331A CN201080041433A CN102574914A CN 102574914 A CN102574914 A CN 102574914A CN 2010800414331 A CN2010800414331 A CN 2010800414331A CN 201080041433 A CN201080041433 A CN 201080041433A CN 102574914 A CN102574914 A CN 102574914A
Authority
CN
China
Prior art keywords
seq
variable region
dom7r
amino acid
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800414331A
Other languages
English (en)
Chinese (zh)
Inventor
E.库尔斯托克
E.德安格里斯
刘海群
O.舍恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN102574914A publication Critical patent/CN102574914A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2010800414331A 2009-07-16 2010-07-14 改进的抗血清清蛋白结合性单可变区 Pending CN102574914A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22602809P 2009-07-16 2009-07-16
US61/226,028 2009-07-16
US30755410P 2010-02-24 2010-02-24
US61/307,554 2010-02-24
PCT/EP2010/060112 WO2011006915A2 (en) 2009-07-16 2010-07-14 Improved anti-serum albumin binding single variable domains

Publications (1)

Publication Number Publication Date
CN102574914A true CN102574914A (zh) 2012-07-11

Family

ID=42829253

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800414331A Pending CN102574914A (zh) 2009-07-16 2010-07-14 改进的抗血清清蛋白结合性单可变区

Country Status (15)

Country Link
US (2) US8679496B2 (https=)
EP (1) EP2454285A2 (https=)
JP (1) JP2012532620A (https=)
KR (1) KR20120038494A (https=)
CN (1) CN102574914A (https=)
AU (1) AU2010272590B2 (https=)
BR (1) BR112012001681A2 (https=)
CA (1) CA2768462A1 (https=)
EA (1) EA201270174A1 (https=)
IL (1) IL217520A0 (https=)
IN (1) IN2012DN00640A (https=)
MX (1) MX2012000765A (https=)
SG (1) SG177601A1 (https=)
WO (1) WO2011006915A2 (https=)
ZA (1) ZA201200276B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108290943A (zh) * 2015-11-13 2018-07-17 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白可变结构域
CN110049997A (zh) * 2016-12-07 2019-07-23 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白单可变结构域
US11897944B2 (en) 2017-01-17 2024-02-13 Ablynx N.V. Immunoglobulin single variable domain (ISVD) capable of binding to serum albumin

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010215479B2 (en) * 2009-02-19 2015-01-22 Glaxo Group Limited Improved anti-TNFR1 polypeptides, antibody variable domains & antagonists
WO2011006915A2 (en) * 2009-07-16 2011-01-20 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
US9012609B2 (en) 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
WO2012072731A2 (en) * 2010-12-01 2012-06-07 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
WO2013068571A1 (en) * 2011-11-11 2013-05-16 Ucb Pharma S.A. Albumin binding antibodies and binding fragments thereof
GB201200563D0 (en) * 2012-01-13 2012-02-29 Imp Innovations Ltd Binding molecule
US20190023809A1 (en) * 2015-09-03 2019-01-24 The Children's Mercy Hospital Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
NO2768984T3 (https=) 2015-11-12 2018-06-09
IL300122A (en) 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
CA3003777A1 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1/ctla4 binders
AU2016355569B2 (en) 2015-11-18 2020-01-02 Merck Sharp & Dohme Llc CTLA4 binders
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
IL263079B2 (en) 2016-05-18 2024-05-01 Modernatx Inc Polynucleotides encoding relaxin
JP7219220B2 (ja) * 2017-01-17 2023-02-07 アブリンクス エン．ヴェー． 改善された血清アルブミン結合剤
HUE070957T2 (hu) 2017-02-16 2025-07-28 Sonnet Biotherapeutics Inc Albuminkötõ domén fúziós fehérjék
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
US12202911B2 (en) 2017-10-10 2025-01-21 Numab Therapeutics AG Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
CN113508134B (zh) 2019-02-22 2024-12-03 安维达生物科技公司 白蛋白结合抗体及其用途
EP3816185A1 (en) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
WO2021205184A1 (en) 2020-04-09 2021-10-14 Autolus Limited Polypeptide
GB202007441D0 (en) 2020-05-19 2020-07-01 Autolus Ltd Polypeptide
EP3915580A1 (en) 2020-05-29 2021-12-01 Numab Therapeutics AG Multispecific antibody
IT202000013006A1 (it) * 2020-06-01 2021-12-01 Bioreweal S R L Processo per la produzione biologica di idrogeno e/o di metano mediante assorbimento e conversione biologica di anidride carbonica.
EP3988568A1 (en) 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
PE20231953A1 (es) 2020-12-07 2023-12-06 UCB Biopharma SRL Anticuerpos multiespecificos y combinaciones de anticuerpos
JP2024504471A (ja) 2021-02-02 2024-01-31 ヌマブ セラピューティックス アーゲー Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
TW202532432A (zh) 2023-09-22 2025-08-16 比利時商艾伯霖克斯公司 二及多價白蛋白結合劑
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
US12459994B2 (en) 2024-04-12 2025-11-04 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007049017A2 (en) * 2005-10-24 2007-05-03 Domantis Limited Agents that bind a target in pulmonary tissue for treating respiratory diseases
WO2008096158A2 (en) * 2007-02-08 2008-08-14 Domantis Limited Antibody single variable domains against serum albumin

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
CA2450793A1 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
ATE479760T1 (de) 2004-03-24 2010-09-15 Domantis Ltd Universelles signalpeptid gas1
TW200607523A (en) 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
CN101128487B (zh) 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
JP2009519011A (ja) * 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
EA200801166A1 (ru) * 2005-12-01 2008-12-30 Домантис Лимитед Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
AU2006323412A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
US20100047171A1 (en) 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
EP2441838A3 (en) * 2006-01-24 2013-07-10 Domantis Limited Fusion proteins that contain natural junctions
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
WO2009149143A1 (en) * 2008-06-03 2009-12-10 E. I. Du Pont De Nemours And Company Adhesion of polyamides to epoxy resins
US8906035B2 (en) * 2008-06-04 2014-12-09 Ethicon Endo-Surgery, Inc. Endoscopic drop off bag
CN102046783A (zh) * 2008-06-06 2011-05-04 丹尼斯科美国公司 包含变体微生物蛋白酶的组合物和方法
US10198891B2 (en) * 2008-06-06 2019-02-05 Epona Llc System and method for regulating fuel transactions
WO2011006915A2 (en) * 2009-07-16 2011-01-20 Glaxo Group Limited Improved anti-serum albumin binding single variable domains

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007049017A2 (en) * 2005-10-24 2007-05-03 Domantis Limited Agents that bind a target in pulmonary tissue for treating respiratory diseases
WO2008096158A2 (en) * 2007-02-08 2008-08-14 Domantis Limited Antibody single variable domains against serum albumin

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108290943A (zh) * 2015-11-13 2018-07-17 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白可变结构域
CN110049997A (zh) * 2016-12-07 2019-07-23 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白单可变结构域
CN110049997B (zh) * 2016-12-07 2023-09-22 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白单可变结构域
US11897944B2 (en) 2017-01-17 2024-02-13 Ablynx N.V. Immunoglobulin single variable domain (ISVD) capable of binding to serum albumin

Also Published As

Publication number Publication date
EA201270174A1 (ru) 2012-07-30
WO2011006915A2 (en) 2011-01-20
MX2012000765A (es) 2012-02-13
BR112012001681A2 (pt) 2019-09-24
US20120114647A1 (en) 2012-05-10
ZA201200276B (en) 2012-09-26
IL217520A0 (en) 2012-02-29
US20140140996A1 (en) 2014-05-22
CA2768462A1 (en) 2011-01-20
EP2454285A2 (en) 2012-05-23
AU2010272590A1 (en) 2012-02-02
US8679496B2 (en) 2014-03-25
AU2010272590B2 (en) 2013-10-10
JP2012532620A (ja) 2012-12-20
WO2011006915A3 (en) 2011-03-03
KR20120038494A (ko) 2012-04-23
IN2012DN00640A (https=) 2015-08-21
SG177601A1 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
CN102574914A (zh) 改进的抗血清清蛋白结合性单可变区
JP5766616B2 (ja) 改良型抗血清アルブミン結合変異体
JP6100315B2 (ja) 改良型抗血清アルブミン結合変異体
US20150284454A1 (en) Anti-serum albumin binding variants
JP2014501515A (ja) 改良された抗血清アルブミン結合単一可変ドメイン
AU2014200157A1 (en) Improved anti-serum albumin binding single variable domains
HK40023197A (en) Improved anti-serum albumin binding variants

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120711